CLAIMS

1. A pharmaceutical composition containing ghrelin or its derivative, wherein pH of an aqueous solution dissolving the ghrelins is from 2 to 7.

2. A pharmaceutical composition according to claim 1, wherein said pH is from 3 to 6.

3. A pharmaceutical composition according to claims 1 or 2, in which a pH adjuster or a buffer agent is further contained.

4. A pharmaceutical composition according to claim 3, wherein the pH adjuster is one or more selected from the group consisting of hydrochloric acid, sulfuric acid, nitric acid, boric acid, carbonic acid, bicarbonic acid, gluconic acid, sodium hydroxide, potassium hydroxide, aqueous ammonia, citric acid, monoethanolamine, lactic acid, acetic acid, succinic acid, fumaric acid, maleic acid, phosphoric acid, methanesulfonic acid, malic acid, propionic acid, trifluoroacetic acid and salt thereof.

5. A pharmaceutical composition according to claim 3, wherein the buffer agent is one or more selected from the group consisting of glycine, acetic acid, citric acid, boric acid, phthalic acid, phosphoric acid, succinic acid, lactic acid, tartaric acid, carbonic acid, hydrochloric acid, sodium hydroxide and the salt thereof.

6. A pharmaceutical composition according to any one of claims 3 to 5, wherein concentration of the pH adjuster or the buffer agent in the solution is in the range of from 0.01mM to 1000mM.

7. A pharmaceutical composition according to any one of claims 1 to 6, wherein the solution is buffer solution.

8. A pharmaceutical composition according to claim 7, wherein the buffer solution is glycine hydrochloride buffer, acetate buffer, citrate buffer, lactate buffer, phosphate buffer, citric acid-phosphate buffer, phosphate-acetate-borate buffer or phthalate buffer.

9. A pharmaceutical composition according to any one of claim 1 to 8, wherein the concentration of the ghrelins in the solution is in the range of 0.03nmol/mL to 6μmol/mL.

10. A pharmaceutical composition according to any one of claims 1 to 9, wherein the ghrelins is acetic acid salt.

11. A pharmaceutical composition according to any one of claims 1 to 10, wherein the ghrelins is human ghrelin.

12. A pharmaceutical composition according to any one of claims 1 to 11, wherein an anti-adsorbent is further contained.

13. A pharmaceutical composition according to claim 12, wherein the concentration of the anti-adsorbent is in the range of from 0.001% to 5%.

14. A pharmaceutical composition according to claim 12 or 13, wherein the anti-adsorbent is surfactant.

15. A pharmaceutical composition containing the ghrelins in which powder obtained from a solution of claimed in any one of claims 1 to 14, by drying is contained.

16. A pharmaceutical composition according to claim 15, wherein the powder is a lyophilized powder.

17. A method for preventing a degradation of hydrophobic group of ghrelin or its derivative in a solution containing the ghrelins which comprises adjusting pH of the solution in the range of from 2 to 7.

18. A method according to claim 17, wherein said pH of the solution is adjusted to 3 to 6.

19. A method according to claims 17 or 18, wherein a pH adjuster or a buffer agent is further contained.

20. A method according to claim 19, wherein one or more pH adjuster selected from the group consisting of hydrochloric acid, sulfuric acid, nitric acid, boric acid, carbonic acid, bicarbonic acid, gluconic acid, sodium hydroxide, potassium hydroxide, aqueous ammonia, citric acid, monoethanolamine, lactic acid, acetic acid, succinic acid, fumaric acid, maleic acid, phosphoric acid, methanesulfonic acid, malic acid, propionic acid, trifluoroacetic acid and salt thereof is contained.

21. A method according to claim 19, wherein one or more buffer agent selected from the group consisting of glycin, acetic acid, citric acid, boric acid, phthalic acid, phosphoric acid, succinic acid, lactic

acid, tartaric acid, carbonic acid, hydrochloric acid, sodium hydroxide and the salt thereof is contained.

22. A method according to any one of claims 19 to 21, wherein concentration of the pH adjuster or the buffer agent in the solution is in the range of 0.01mM to 1000mM.

23. A method according to any one of claims 17 to 22, wherein the solution is buffer solution.

24. A method according to claim 23, wherein the buffer solution is glycine hydrochloride buffer, acetate buffer, citrate buffer, lactate buffer, phosphate buffer, citric acid-phosphate buffer, phosphate-acetate-borate buffer or phthalate buffer.

25. A method according to any one of claim 17 to 24, wherein the concentration of the ghrelins in the solution is in the range of from 0.03nmol/mL to 6μmol/mL.

26. A method according to any one of claims 17 to 25, wherein the ghrelins is acetic acid salt.

27. A method according to any one of claims 17 to 26, wherein the ghrelins is human ghrelin.